NPPA To Appoint Agency For Providing Data And Information On Pharmaceutical Products

Mumbai : The National Pharmaceutical Pricing Authority (NPPA) will soon appoint agency for providing data and information on pharmaceutical products.

The agency is envisaged to provide data and information on pharmaceutical products in the country overall, and also to provide segment, company, region and state-wise data, and the likes. For this purpose, the national drug price regulator has invited agencies and companies having capacity and proven track record of providing similar data and information.

The agency shall primarily be required to provide data as follows on a specific need basis, data on availability and price may be sought from the agency from time to time. Data on availability (overall/State-wise/city-wise) on specific formulation(s) and/or therapeutic group(s) may be asked for.

Data sought will be on pack-wise monthly data of sales units, mat units, monthly sales value, mat sales value units consisting classification (Scheduled/Non Scheduled/Para 19/New drug), Sub group, Brand Name, SKU, Brand & Sub- Group launch date, Therapy, Company Name, Strength and Marketing Company Name, Pack Size, Doses Form, Drug Type, NLEM 15, NLEM 11, GST Rate, Ceiling Price, S.O. Date & S.O. No., MRP, PTR, PTS, % Market Share etc.

It also includes pack-wise monthly data of pharma products consisting of SKU Name, brand and company name, company address classification (Scheduled/ Non- scheduled/Para 19/New drug), Sales Quantity, MRP, PTR & PTS (excluding GST), ceiling price, retail price of new drugs, % market share, GST Rate and marketing company name etc.

Non-scheduled price violation report pack-wise monthly data of pharma products regarding price violation in context of para 20; consisting of SKU Name, brand & company name, company address, sales quantity, MRP and marketing company name etc.

Pack-wise monthly data of pharma products consisting of SKU Name, brand & company name, company address, sales quantity, MRP, PTR & PTS (excluding GST), ceiling price, retail price of new drugs, % market share, GST Rate and marketing company name etc.

The agency should be able to provide the services as per the “Scope of Work”. Each agency shall submit Bids for the work under- Technical Bid, Financial Bid. Additional value added data/information/reports as proposed by the agency that can be submitted on monthly/quarterly/yearly basis. The above should be based on the total financial impact of the annual contract for the work, including taxes.

For the purpose, the NPPA has now issued an online notice inviting tender (NIT) from prospective agencies.This NIT is in supersession of the NIT published on August 19, 2020.

As per the notice, interested agencies or companies who meet the eligibility criteria, may furnishtheir bids against this NIT, along with all the necessary documents and the covering letter, tender acceptance letter, signed and stamped by an authorized signatory online at https://eprocure.gov.in/eprocure/app on or before December 18, 2020 by 4 PM. Manual bids shall not be accepted.

The bids are to be submitted online only. Bids submitted by fax or e-mail, etc. shall not be considered. No further correspondence on the subject will be entertained.

Tender Document may be downloaded from Central Public Procurement Portal (CPPP) site https://eprocure.gov.in/eprocure/app.

Companies have been asked to submit their bids against a NIT for providing data and information on pharmaceutical products. The eligible companies should have the capacity and proven track record of providing data and information as per the prescribed scope of work of NPPA.

Submission of bids in response to this NIT shall be deemed to have been done after careful study and examination with full understanding of its terms, conditions and implications.

Related Posts

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

Pak-made illegal cosmetics recovered from Itwari shop

Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert